» Articles » PMID: 31409849

Fluoroquinolone Heteroresistance in Mycobacterium Tuberculosis: Detection by Genotypic and Phenotypic Assays in Experimentally Mixed Populations

Overview
Journal Sci Rep
Specialty Science
Date 2019 Aug 15
PMID 31409849
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Heteroresistance - the simultaneous presence of drug-susceptible and -resistant organisms - is common in Mycobacterium tuberculosis. In this study, we aimed to determine the limit of detection (LOD) of genotypic assays to detect gatifloxacin-resistant mutants in experimentally mixed populations. A fluoroquinolone-susceptible M. tuberculosis mother strain (S) and its in vitro selected resistant daughter strain harbouring the D94G mutation in gyrA (R) were mixed at different ratio's. Minimum inhibitory concentrations (MICs) against gatifloxacin were determined, while PCR-based techniques included: line probe assays (Genotype MTBDRsl and GenoScholar-FQ + KM TB II), Sanger sequencing and targeted deep sequencing. Droplet digital PCR was used as molecular reference method. A breakpoint concentration of 0.25 mg/L allows the phenotypic detection of ≥1% resistant bacilli, whereas at 0.5 mg/L ≥ 5% resistant bacilli are detected. Line probe assays detected ≥5% mutants. Sanger sequencing required the presence of around 15% mutant bacilli to be detected as (hetero) resistant, while targeted deep sequencing detected ≤1% mutants. Deep sequencing and phenotypic testing are the most sensitive methods for detection of fluoroquinolone-resistant minority populations, followed by line probe assays (provided that the mutation is confirmed by a mutation band), while Sanger sequencing proved to be the least sensitive method.

Citing Articles

Speeding up drug susceptibility testing in Mycobacterium tuberculosis using RNA biomarkers.

Sury A, Maex M, Baulard A, Bhattacharyya R, Depickere S, Hung D EBioMedicine. 2025; 113:105611.

PMID: 40010155 PMC: 11905850. DOI: 10.1016/j.ebiom.2025.105611.


Impacts of MDR/XDR-TB on the global tuberculosis epidemic: Challenges and opportunities.

Chin K, Anibarro L, Chang Z, Palasuberniam P, Mustapha Z, Sarmiento M Curr Res Microb Sci. 2024; 7:100295.

PMID: 39512261 PMC: 11541417. DOI: 10.1016/j.crmicr.2024.100295.


Genetic Characterization and Population Structure of Drug-Resistant Isolated from Brazilian Patients Using Whole-Genome Sequencing.

Esteves L, Gomes L, Brites D, Fandinho F, Bhering M, Pereira M Antibiotics (Basel). 2024; 13(6).

PMID: 38927163 PMC: 11200758. DOI: 10.3390/antibiotics13060496.


Rapid Diagnosis of Drug-Resistant Tuberculosis-Opportunities and Challenges.

Naidoo K, Perumal R, Ngema S, Shunmugam L, Somboro A Pathogens. 2024; 13(1).

PMID: 38251335 PMC: 10819693. DOI: 10.3390/pathogens13010027.


Mixed infections in genotypic drug-resistant Mycobacterium tuberculosis.

Wang L, Campino S, Phelan J, Clark T Sci Rep. 2023; 13(1):17100.

PMID: 37816829 PMC: 10564873. DOI: 10.1038/s41598-023-44341-x.


References
1.
Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F . Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother. 2009; 53(10):4498-500. PMC: 2764174. DOI: 10.1128/AAC.00287-09. View

2.
Roh S, Smith L, Lee J, Via L, Barry 3rd C, Alland D . Comparative Evaluation of Sloppy Molecular Beacon and Dual-Labeled Probe Melting Temperature Assays to Identify Mutations in Mycobacterium tuberculosis Resulting in Rifampin, Fluoroquinolone and Aminoglycoside Resistance. PLoS One. 2015; 10(5):e0126257. PMC: 4418795. DOI: 10.1371/journal.pone.0126257. View

3.
Zetola N, Shin S, Tumedi K, Moeti K, Ncube R, Nicol M . Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol. 2014; 52(7):2422-9. PMC: 4097703. DOI: 10.1128/JCM.02489-13. View

4.
Streicher E, Bergval I, Dheda K, Bottger E, Gey van Pittius N, Bosman M . Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. Antimicrob Agents Chemother. 2012; 56(5):2420-7. PMC: 3346650. DOI: 10.1128/AAC.05905-11. View

5.
Pholwat S, Stroup S, Foongladda S, Houpt E . Digital PCR to detect and quantify heteroresistance in drug resistant Mycobacterium tuberculosis. PLoS One. 2013; 8(2):e57238. PMC: 3584134. DOI: 10.1371/journal.pone.0057238. View